Acrivon Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021
Market Capitalization	294	109	241	-
Market Cap Growth	-	-54.61%	-	-
Enterprise Value	170	-14	117	-94
PE Ratio	-1.81	-1.81	-7.72	-
PB Ratio	2.42	0.90	1.41	-
P/FCF Ratio	-2.49	-2.49	-7.45	-
P/OCF Ratio	-2.56	-2.56	-7.99	-
EV/EBITDA Ratio	0.24	0.24	-3.90	6.12
EV/EBIT Ratio	0.23	0.23	-3.77	5.81
EV/FCF Ratio	0.32	0.32	-3.64	6.64
Debt / Equity Ratio	0.04	0.04	0.03	-0.24
Debt / EBITDA Ratio	-0.08	-0.08	-0.16	-0.37
Debt / FCF Ratio	-0.11	-0.11	-0.15	-0.40
Quick Ratio	9.61	9.61	19.67	34.31
Current Ratio	9.75	9.75	20.27	34.46
Return on Equity (ROE)	-42.50%	-42.50%	-42.50%	100.80%
Return on Assets (ROA)	-39.00%	-39.00%	-21.70%	-29.90%
Return on Capital (ROIC)	-53.32%	-53.32%	-18.61%	89.02%
Earnings Yield	-20.57%	-55.30%	-12.95%	-
FCF Yield	-14.96%	-40.23%	-13.42%	-
Buyback Yield / Dilution	-435.63%	-435.63%	-136.43%	-21.70%
Total Shareholder Return	-435.63%	-435.63%	-136.43%	-21.70%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).